Anticholinergic burden measures predict older people's physical function and quality of life: A systematic review by Stewart, Carrie et al.
Review	Article
Anticholinergic	Burden	Measures	Predict	Older	People's	Physical	Function	and	Quality	of	Life:	A	Systematic	Review
Carrie	Stewart,	PhDa,	∗
carrie.stewart@abdn.ac.uk,	carrie.stewart1@outlook.com
Kaisa	Yrjana,	BSca
Mitrysha	Kishor,	BSca
Roy	L.	Soiza,	MDb
Martin	Taylor-Rowan,	PhDc
Terence	J.	Quinn,	MDc
Yoon	K.	Loke,	MDd
Phyo	Kyaw	Myint,	MDa,	b
aAging	Clinical	and	Experimental	Research	(ACER)	Group,	Institute	of	Applied	Health	Sciences,	University	of	Aberdeen,	Aberdeen,	Scotland,	UK
bAberdeen	Royal	Infirmary,	NHS	Grampian,	Aberdeen,	Scotland,	UK
cInstitute	of	Cardiovascular	and	Medical	Sciences,	University	of	Glasgow,	Glasgow,	UK
dNorwich	Medical	School,	University	of	East	Anglia,	Norwich,	UK
∗Address	correspondence	to	Carrie	Stewart,	PhD,	Aging	Clinical	and	Experimental	Research	(ACER)	Group,	Institute	of	Applied	Health	Sciences,	Rm	1.128,	Polwarth	Building,	University	of	Aberdeen,	Foresterhill	Health	Campus,
Aberdeen,	AB25	2ZD,	UK.
This	work	was	supported	by	The	Dunhill	Medical	Trust	(grant	number	RPGF1806/66).	Our	funder	(Dunhill	Medical	Trust)	had	no	role	in	the	design,	methods,	data	collection,	analysis	or	preparation	of	this	manuscript.
The	authors	declare	no	conflicts	of	interest.
Abstract
Objectives
This	systematic	review	(PROSPERO	CRD42019115918)	compared	the	evidence	behind	anticholinergic	burden	(ACB)	measures	and	their	ability	to	predict	changes	in	older	people's	physical	function	and	quality	of	life.
Design
Eligible	cohort	or	case-control	studies	were	identified	systematically	using	comprehensive	search	terms	and	a	validated	search	filter	for	prognostic	studies.	Medline	(OVID),	EMBASE	(OVID),	CINAHL	(EMBSCO),	and
PsycINFO	(OVID)	databases	were	searched.	Risk	of	bias,	using	Quality	 in	Prognosis	Studies	tool,	and	quality	of	evidence,	using	the	Grading	of	Recommendations,	Assessment,	Development	and	Evaluation	GRADE,	were
assessed.
Setting	and	Participants
People	age	65	years	and	older	from	any	clinical	setting.
Measures
Any	ACB	measures	were	accepted	(including	the	anticholinergic	domain	of	the	Drug	Burden	Index).	Any	global/	multidimensional	measure	for	physical	function	and/	or	quality	of	life	was	accepted	for	outcome.
Results
Physical	 function	and	quality	of	 life	are	2	 important	health	outcomes	 for	older	people.1	Physical	 function	 focuses	upon	an	 individual's	activities	and	participation,	particularly	 in	 relation	 to	what	would	be
considered	normal	general	daily	tasks,	self-care	activities,	and	participation	in	community	and	social	interactions.2	Quality	of	life	overlaps	this,	defined	as	“a	broad	ranging	concept	affected	in	a	complex	way	by	the
person's	physical	health,	psychological	state,	personal	beliefs,	social	relationships,	and	their	relationship	to	salient	features	of	their	environment.”3	Quality	of	life	is	concerned	more	with	the	impact	of	activity	and
participation	limitations	upon	well-being.4	Both	outcomes	are	considered	key	research	priorities	by	both	older	people	and	health	professionals.1
Understanding	what	influences	these	outcomes	is	important;	factors	which	are	modifiable	can	be	targeted	to	improve	older	people's	physical	function	and	quality	of	life.	One	potentially	important	factor	is
anticholinergic	burden	(ACB),5,6	the	accumulation	of	anticholinergic	effects	from	one	or	more	anticholinergic	medications.7,8	Medications	with	anticholinergic	properties	are	prescribed	for	a	range	of	common	problems
in	older	age,	including	urinary	incontinence,	depression,	and	gastrointestinal	complaints.8,9	Side-effects	include	confusion,	constipation,	delirium,	dizziness,	drowsiness,	and	dry	mouth.8,9	Studies	estimate	up	to	50%	of
community-dwelling	older	adults	use	one	or	more	anticholinergic	medications.10,11	However,	in	addition	to	being	the	greatest	consumers	of	anticholinergic	medications,	older	people	are	more	susceptible	to	side	effects
and	adverse	outcomes.8	To	date,	although	a	number	of	reviews	in	this	area	have	included	older	people,	few	reviews	have	specifically	restricted	inclusion	and	analysis	to	older	people.	Therefore,	there	is	an	urgent	need
to	understand	anticholinergic	use	and	its	consequences	within	the	older	adult	population.
Several	factors	presently	limit	advancing	knowledge	in	this	area,	not	least	study	design	and	choice	of	ACB	measure.	Our	previous	(unpublished)	research	identified	14	ACB	measures	reported	in	the	literature.
The	variation	in	ACB	measures	makes	interpretation	challenging;	the	ACB	measures	differ	substantially.12,13	The	number	of	medications	assessed	in	each	scale	varies	from	27	in	the	ACB	Classification	to	117	in	the
Anticholinergic	Drug	Scale	(ADS).13	The	potency	score	for	individual	medications	also	varies	between	scales.13	For	example,	Nortriptyline	is	rated	as	having	high	anticholinergic	activity	by	Boustani	et	al	(2008)	in	the
Anticholinergic	Cognitive	Burden	Scale14	but	moderate	by	Rudolph	et	al	(2008)	in	the	Anticholinergic	Risk	Scale	(ARS).15	As	yet	no	evidence	provides	clear	rationale	to	support	use	of	one	measure	above	another.	In
addition,	many	reviews	have	included	cross-sectional	study	designs,	restricting	our	understanding	of	the	temporal	relationship	between	ACB	and	future	outcomes.	There	is	a	need	to	explore	the	ability	of	individual
ACB	measures	to	predict	these	outcomes	and	identify	if	one	ACB	measure	performs	better	than	another.	Understanding	the	prognostic	utility	of	ACB	measures	will	enhance	future	outcome	reporting	for	trials	seeking
to	reduce	ACB.
This	systematic	review	aims	to	describe	the	association	of	individual	ACB	measures	with	physical	function	and	quality	of	life,	and	to	compare	the	prognostic	utility	of	ACB	measures.
Methods
This	 PROSPERO	 registered	 systematic	 review	 (CRD42019115918,	 Available	 at:	 http://www.crd.york.ac.uk/PROSPERO)	 was	 conducted	 using	 the	 Cochrane	 Prognostic	 Review	 Group	 Framework	 for	 Prognostic	 Reviews
(https://methods.cochrane.org/prognosis/our-publications)16	and	reported	in	accordance	with	Preferred	Reporting	Items	for	Systematic	Reviews	and	Meta-analyses	(PRISMA)	(Supplementary	File	1	for	PRISMA	Checklist).
Literature	Search	Strategy
The	search	strategy	was	developed	following	extensive	scoping	searches	to	identify	appropriate	MeSH	and	other	controlled	vocabulary	for	ACB	and	ACB	measures.	We	employed	a	validated	search	filter	for	the	identification	of
prognostic	studies.17	The	strategy	was	modified	to	suit	each	database	searched	[MEDLINE	(Ovid),	EMBASE	(Ovid),	CINAHL	(EBSCO),	and	PsycINFO	(Ovid)].	Searches	were	from	January	1,	2006	to	March	4,	2020.	The	2006	inception
was	chosen	as	the	time	when	ACB	was	first	conceptualized	and	studied.	The	full	strategy	is	reported	in	our	Supplementary	File	1.
Thirteen	studies	reporting	associations	between	ACB	and	physical	function	(n	=	10)	or	quality	of	life	(n	=	4)	were	included.	Exposure	measures	included	Anticholinergic	Cognitive	Burden	Scale,	Anticholinergic	Drug
Scale,	Anticholinergic	Risk	Scale,	Clinician	Rated	Anticholinergic	Score,	and	 the	anticholinergic	domain	of	 the	Drug	Burden	 Index.	All	 studies	were	 rated	moderate	 risk	of	bias	 in	≥2	QUIPSQuality	 in	Prognosis	Studies
categories	with	5	rated	high	risk	in	≥1	categories.	Seven	of	10	studies	(5251	of	7569	participants)	reported	significant	decline	in	physical	function	with	increased	burden.	All	4	studies	(2635	participants)	reporting	quality	of
life	demonstrated	similar	association	with	increased	burden.	High	risk	of	biases	and	inadequate	data	reporting	restricted	analysis.	There	was	no	evidence	to	support	one	measure	being	superior	to	another.
Conclusions	and	Implications
The	evidence	supports	association	between	increased	ACB	and	future	impairments	in	physical	function	and	quality	of	life.	No	conclusion	can	be	made	regarding	which	ACB	measure	has	the	best	prognostic	value.	Well-
designed	longitudinal	studies	are	required	to	address	this.	Clinicians	should	be	aware	of	patient's	anticholinergic	burden	and	consider	alternative	medications	where	appropriate.
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Inclusion	Criteria
The	following	criteria	were	applied	to	identify	appropriate	studies:	(1)	Report	a	prospective	or	retrospective	observational	study	(longitudinal	cohort	or	case-control);	(2)	Involve	adults	age	≥65	years	(or	mean	age	≥65	years);
(3)	Assess	ACB	exposure	using	any	ACB	measure	[to	include	anticholinergic	(Ach)	domain	of	the	Drug	Burden	Index	(DBI)];	(4)	Any	length	of	follow-up	period;	and	(5)	Report	any	global/	multi-dimensional	measure	of	physical	function
and/	or	quality	of	life	as	an	outcome.
Exclusion	Criteria
The	following	exclusion	criteria	were	applied:	(1)	Studies	restricted	to	measuring	classes	of	or	specific	anticholinergic	medications	(eg,	psychotropics);	and	(2)	Measure	of	medications	not	specifically	directed	at	anticholinergic
drugs	(eg,	Beers	criteria).
Study	Selection	Process
Searches	were	 conducted	 on	 the	November	 16,	 2018,	 then	updated	 on	March	 4,	 2020	 and	 identified	 studies	 transferred	 to	Covidence	 systematic	 review	 software	 2019	 (Veritas	Health	 Innovation	Ltd,Melbourne	 Australia,
www.covidence.org).	After	duplicates	were	removed,	13,394	studies	remained.	These	were	then	screened	by	title	and	abstract	by	2	independent	reviewers	(shared	between	C.S.,	K.Y.,	M.K.).	Both	primary	reviewers	had	to	agree	upon
exclusion	and,	where	this	was	not	the	case,	a	third	independent	reviewer	made	the	final	decision	(T.Q.).	The	full	text	of	remaining	studies	(n	=	124)	were	screened	by	2	independent	reviewers	(shared	between	C.S.,	K.Y.,	M.K.).	Again,	a
third	independent	reviewer	resolved	any	disagreements	(T.Q.).	Exclusion	reasons	are	reported	in	the	identified	PRISMA	flow	chart	(Supplementary	File	1).	Reference	lists	of	included	studies	were	searched,	and	citations	via	PubMed
reviewed,	to	check	for	studies	our	search	had	omitted.	Reference	lists	and	citations	of	recent	seminal	articles13,18	were	also	searched.	No	additional	studies	for	inclusion	were	identified.	Thirteen	articles	remained	that	reported	physical
function	or	quality	of	life	as	an	outcome.
Data	Collection	and	Extraction
A	data	extraction	template	was	developed	in	accordance	with	guidance	by	the	Cochrane	Prognostic	Review	Group	framework	(https://methods.cochrane.org/prognosis/our-publications).16	This	included	study	characteristics	(eg,
year	of	publication,	country,	study	setting),	measures	assessed,	timing	and	methods	of	assessments,	statistical	plan,	confounders/	adjustments	and	results.	Two	reviewers	(shared	between	C.S.,	K.Y.,	M.K.)	independently	extracted	data
and	a	third	reviewer	arbitrated	any	disagreements	(T.Q.).	Data	were	then	transferred	to	a	Microsoft	Excel	2016	(Microsoft	Corporation,	California,	USA,	https://products.office.com/en-gb/excel)	sheet	and	imported	to	Comprehensive	Meta-
Analysis	v	3.3.070	(Biostat,	New	Jersey,	USA,	https://www.meta-analysis.com/)	for	analysis.
Risk	of	Bias
Risk	 of	 bias	 for	 each	 included	 study	 was	 assessed	 using	 the	 Quality	 in	 Prognosis	 Studies	 tool,	 developed	 by	 the	 Cochrane	 Prognosis	 Methods	 Group	 (QUIPS,	 Available	 at:
https://methods.cochrane.org/sites/methods.cochrane.org.prognosis/files/public/uploads/QUIPS%20tool.pdf).19	Risk	of	bias	is	assessed	across	6	domains:	study	participation,	attrition,	prognostic	measurement,	outcome	measurement,
study	confounding,	and	statistical	analysis.	As	recommended,	we	took	the	QUIPS	anchoring	statement	and	modified	the	wording	to	suit	our	review	question.	We	agreed	to	accept	any	baseline	measure	of	ACB	and	for	statistical	analysis
we	agreed	within	the	research	team	a	minimum	level	of	adjustment	(set	of	confounders)	that	would	constitute	high	quality	(discussed	further	below).	Assessments	were	conducted	by	those	who	completed	data	extraction	(C.S.,	K.Y.,
M.K.)	and	any	disagreements	arbitrated	by	a	third	reviewer	(T.Q.).	Publication	bias	was	planned	to	be	assessed	by	way	of	funnel	plot.
Analysis
All	 included	studies	underwent	narrative	analysis	 following	the	guidance	provided	by	the	European	Social	Research	Council.20	Findings	were	assessed	qualitatively	considering	clinical	heterogeneity	and	the	risk	of	biases.
Patterns	of	associations	across	the	studies	were	also	explored	and	described.	Association	data	extracted	included	odds	ratios,	risk	ratios,	their	respective	confidence	intervals,	β	values,	standard	error,	and	P	values,	where	reported.
Baseline	and	follow-up	scores	for	ACB	and	relevant	outcome	were	recorded	if	reported.	Pooled	analysis	was	planned	with	summary	statistics	where	possible	for	both	adjusted	and	unadjusted	data.
Which	factors	and	what	constitutes	minimum	adjustment	were	determined	by	consensus,	using	a	Delphi	approach	involving	the	senior	authors	(C.S.,	R.S.,	Y.L.,	P.M.).	It	was	agreed	after	one	round	that	minimum	adjustment
would	be	age	and	sex	and	≥1	comorbidities	(or	a	global	measure	of	the	number	of	comorbidities).	Where	possible	forest	plots	and	meta-analyses	using	random	effects	modeling	techniques	were	planned	to	graphically	and	statistically
demonstrate	the	body	of	evidence.	Results	were	analyzed	according	to	our	hierarchy	of	research	questions:	(1)	Prognostic	utility	of	individual	ACB	measures	for	each	outcome	of	interest	(all	measures	for	either	physical	function	or
quality	of	life	combined);	and	(2)	Comparison	of	prognostic	utilities	of	ACB	measures	for	each	outcome	of	interest	(all	measures	for	either	physical	function	or	quality	of	life	combined)
Quality	Assessment
The	the	Grading	of	Recommendations,	Assessment,	Development	and	Evaluation	(GRADE)	assessment	tool	was	used	to	determine	the	quality	of	the	body	of	evidence	for	each	scale	and	outcome.	The	GRADE	approach	assesses	the
evidence	across	all	studies	analyzed	for	a	given	outcome,	rather	than	assessing	the	evidence	from	each	study	individually.21	The	GRADE	framework	allows	the	quality	of	the	evidence	to	be	judged	across	criteria	known	to	limit	the
quality	of	evidence.21	Guidance	for	applying	GRADE	to	prognostic	studies	was	taken	from	Huguet	et	al	(2013).22	Quality	was	assessed	across	7	criteria;	study	limitations,	inconsistency,	indirectness,	imprecision,	publication	bias,	effect
size,	and	dose-effect.	Further	details	regarding	these	criteria	can	be	found	on	the	GRADE	website	(http://www.gradeworkinggroup.org).
Results
Of	the	13	studies,23–35	10	reported	associations	between	ACB	and	physical	function23,24,26,27,29–34	and	4	reported	associations	with	quality	of	life.23,25,28,35	One	study23	is	reported	twice	as	it	reports	both	outcomes.	Five	measures
for	ACB	exposure	were	included	Anticholinergic	Cognitive	Burden	Scale	(ACBS),	ADS	[modified	Clinician	Rated	Anticholinergic	Score	(mCRAS)],	ARS,	CRAS,	and	the	DBI-Ach.	Each	scale	was	developed	within	the	United	States.	The
ACBS	assesses	88	medications	considered	by	expert	opinion	to	have	anticholinergic	properties	which	have	significant	impact	upon	cognition.24	The	ADS	assesses	117	medications	which	are	scored	based	on	each	medications	serum
anticholinergic	activity	as	published	in	the	existing	literature.13,35	The	ADS	was	originally	known	as	the	modified	Clinician	Rated	Anticholinergic	Score.13	The	ARS	assesses	49	medications	considered	to	have	anticholinergic	properties
which	have	significant	 impact	on	both	cognitive	and	physical	 function.24	The	Clinician	Rated	Anticholinergic	Score	assess	60	medications,	 identified	 from	several	ACB	scales,	 considered	strongly	 implicated	 in	 the	development	of
delirium.13,26	The	anticholinergic	domain	of	the	DBI	is	somewhat	different	from	other	ACB	measures	in	that	it	considers	dose	and	duration	of	use	of	individual	anticholinergic	medications.28	It	was	also	developed	based	upon	existing
literature	and	expert	opinion.28
Physical	Function
Descriptive	details	for	each	study	are	presented	in	Table	1.	In	total	7569	older	people	participated	across	the	10	studies,	with	mean	(±	standard	deviation)	ages	ranging	from	71.9	(12.0)	years23	to	86.1	(6.8)	years.29	Three
studies	were	conducted	in	Italy,24,32,34	3	in	the	US,26,29,31	and	1	each	from	Australia,23	Israel,27	Spain,33	and	the	United	Kingodm.30
Table	1	Characteristics	of	Studies	Reporting	Association	Between	ACB	and	Physical	Function	(n	=	10)	and	QoL	(n	=	4)
Studies Design n Age,	y	(Mean,	SD) Sex	Male	(n,
%)
Country Setting Follow-Up	Duration ACB	Measure Function
Measure
QoL
Measure
Agar	et	al	200923 Prospective 461∗ 71.9	(12.0) 232	(50.0) Australia Palliative	care Death	(mean
107	d)
CRAS AKPS MQoL
Brombo	et	al	201824 Retrospective 1123 81.0	(7.4) 494	(44.0) Italy Acute	care	(hospital) 1	y ARS	and	ACBS ADL	(Katz) –
Cossette	et	al	201725 Prospective 1793 74.4	(4.2) 853	(48) Canada Community 36	mo ACBS,	ADS	and
ARS
– SF-36
Han	et	al	200826 Prospective 544 74.4	(5.2) 544	(100.0) USA Primary	care	clinic 1	y mCRAS IADL	(OARS) –
Hershkovitz	et	al
201827
Retrospective 869 83.4	(6.9)† 41	(20.2) Israel Geriatric	rehabilitation	center Discharge	(mean
NR)
ACBS FIM –
Ie	et	al	201728 Retrospective 426 78.6	(6.72) 48	(11.3) USA Care	homes	and	Community 12	mo ACBS	and	DBI-
Ach
– EQ-5D
Kolanowski	et	al
201529
Prospective 99 86.1	(6.8) 22	(32.0) USA Post-acute	care	(hospital) Discharge	(mean
NR)
ACBS BI –
Koshoedo	et	al	201230 Prospective 105 79.0	(7.0) 29	(25.0) UK Orthopedic	rehabilitation	unit Discharge	(mean
15	d)
ARS BI –
Koyama	et	al	201431 Prospective 1429 83.0	(3.1) 0	(0.0) USA Community 5	y ACBS IADL	(NS) –
Landi	et	al	201432 Prospective 1490 83.6	(65.1–106.4)‡ 425	(28.5) Italy Nursing	home 1	y ARS ADL	(MDS-HC) –
Lopez-Matons	et	al Retrospective 126 80.0	(6.7) 28	(27.8) Spain Geriatric	clinic	(hospital) 1	y ACBS BI –
201833
Pasina	et	al	201334 Retrospective 1323 79.9	(7.3)† 51	(49.7) Italy internal	medicine	and	geriatric	wards
(hospital)
3	mo ARS	and	ACBS BI –
Sura	et	al	201635 Retrospective 112 Age	65.00	–	79.0
(n	=	59)
Age	≥80	(n	=	53)
48	(42.9) USA Community 24	mo ADS – SF-12
ADL,	activities	of	daily	living;	AKPS,	Australian-Modified	Karnofsky	Performance	Status;	BI,	Barthel	Index;	EQ-5D,	EuroQol	5D;	FIM,	Functional	Independence	Measure;	IADL,	instrumental	activities	of	daily	living;
MDS-HC;	Minimum	Data	Set	for	Home	Care;	MQoL,	MacGill	Quality	of	Life	Score;	NR,	not	reported;	NS;	not	specified;	OARS,	Older	American	Resources	and	Services;	QoL,	quality	of	life;	SD,	standard	deviation;	SF-
12,	Short	Form	Health	Survey	12.
∗ 461	participants	recruited	but	QoL	analysis	conducted	with	304	participants	who	died	during	study	follow-up.
†Mean	age	for	ACB	users	within	sample.
‡Median	and	interquartile	range	presented	instead	of	mean	(SD).
Risk	of	bias	for	each	study	(n	=	10)	is	presented	in	Figure	1.	Of	the	10	studies,	4	papers	were	considered	high	risk	of	bias	≥1	QUIPS	categories.23,29,31,34	High	risk	of	bias	arose	most	commonly	from	issues	around	participation,
including	poor	descriptions	of	sample	group,23	inadequate	description	of	those	excluded,31	or	little	information	regarding	participation	rate.29	Moderate	risks	of	bias	were	common	throughout	all	studies;	attrition	(the	number,	reasons
for	or	exploration	of	outcome	factors	in	those	lost)	was	rarely	addressed.	A	funnel	plot	for	assessing	publication	bias	was	not	possible	due	to	variation	in	statistical	effect	sizes	presented	and	too	few	studies.
ACB	Scale	and	Physical	Function
Six	studies,	with	sample	sizes	ranging	from	n	=	9929	to	n	=	142931	explored	the	relationship	between	baseline	ACB	and	future	physical	function	using	the	ACBS	(Table	2).	Three	studies	reported	significant	associations	between
increased	ACB	and	impaired	physical	function24,29,31	with	little	difference	between	unadjusted	and	adjusted	results.	Brombo	et	al	201824	reported	the	strongest	association	between	increased	ACBS	score	and	a	decline	in	activities	of
Fig.	1	QUIPS	Risk	of	bias	assessment	of	studies	reporting	association	between	ACB	and	physical	function	(n	=	10)	and	quality	of	life	(n	=	4).
daily	living	scores	[2.77,	95%	confidence	interval	(CI)	1.39,	5.54].	Inconsistencies	between	studies	regarding	statistical	analysis	and	data	presented	limited	further	analysis.	For	example,	as	shown	in	Table	2	the	6	studies	utilized	4
different	physical	function	outcome	measures	and	varied	in	comparison	groups	(eg,	ACBS	=	0	vs	ACBS	≥1	or	ACBS	≤	1	vs	ACBS	≥2).
Table	2	Summary	of	Results	for	Studies	Exploring	Prognostic	Relationships	Between	ACB	Scale	and	Physical	Function	(n	=	10)
Scale/Outcome Studies ACB
(Baseline)
Physical	Function	(Baseline) Statistical
Approach
Results	(Unadjusted) Results	(Adjusted)
ACBS	(Range	0–3)
 ADL	(≥1	ADL) Brombo	et	al	201824 ACBS	≤1:
381	(33.9%)
Any	ADL:	542	(48.3%) Multivariable
logistic
regression
OR	95%	CI
(ACBS	≥1	vs
ACBS	=	0)
2.38	(1.37,4.13)	P	=	.002 2.77	(1.39,	5.54)	P	=	.004∗
ACBS	≥2:
348	(31.0%)
 BI	(Range	0–100) Kolanowski	et	al	201529 ACBS	Mild:
81	(81.8%)
NR Multiple	linear
regression
β	(SE)
NR Mild:	−3.41	(2.14)	P	=	NS†
ACBS
Mod/Sev:	25
(25.2%)
Mod/sev:	5.76	(1.99)	P	≤	.05
Lopez-Matons	et	al	201833 ACBS	≥1:
26.4%
BI	(Mean,	SD):	88.9	(18.5) Difference	in	the
BI	scores
between	exposed
and	unexposed
patients	Mean
(SD)	(95%	CI)
−4.3	(3.3)
(−10.8,	−2.2)
−4.0	(4.5)
(−12.9,	4.9)‡
Pasina	et	al	201334 ACBS	≥1:
724	(58.8%)
NR Correlation
Pearson
coefficient
0.004,	P	=	.91 NR
 FIM	(Range	18–126) Hershkovitz	et	al	201827 ACB	≤1:	666
(76.6%)
60.5	(17.8) Multiple	linear
regression
β	(SE)
NR −0.03	(0.85)	P	=	.02§
ACB	≥2:	203
(23.4%)
56.3	(18.7)
 IADL	(Range	0–8) Koyama	et	al	201431 ACBS	Mean
(SD):	1.6
(1.9)
NR Multiple	logistic
regression
OR	(95	%	CI)
1.11	(1.04,	1.18)	P	=	NR 1.11	(1.04,	1.19)‖	P	=	NR
ARS	(Range	0–3)
 ADL	(Range	0–28) Brombo	et	al	201824 ARS	≥1:	208
(18.5%)
ADL	any:	542	(48.3%) Multivariable
logistic
regression
OR	95%	CI
2.43	(1.26,4.68)	P	=	.008 1.49	(0.60,	3.70)	P	=	.38∗
Landi	et	al	201432 ARS	≥1:	721
(48.4%)
ADL	Mean	(SD):	15.4	(10.3) Multivariable
logistic
regression
OR	(95%	CI)
NR 1.13	(1.03,	1.23)	P	=	.01∗∗
 BI	(Range	0–100) Koshoedo	et	al	201230 ARS	Median BI	Median	(IQR):	55	(40–60) Poisson NR 0.97	(0.95,	0.99)	P	=	.008††
(IQR):	0
(0–1)
regression
IRR	(95%	CI)
Pasina	et	al	201334 ARS	≥1:	112
(9.1%)
NR Correlation
Pearson
coefficient
−0.06	P	=	.15 NR
CRAS/mCRAS	(Range	0–3)
 AKPS	(Range	0–100) Agar	et	al	200923 NR AKPS	(Mean,	SD):	61.0	(13.8) Logistic
regression
OR	(95%	CI)
NR 0.85	(0.81,	0.90)	P	=	NR‡‡
 IADL	(Range	0–8) Han	et	al	200826 CRAS
Mean	(SD):
1.3	(1.5)
IADL
Mean	(SD):	6.5	(1.07)
Mixed	effects
linear	regression
Effect	estimate
(95%	CI)
0.16	(0.11,	0.25)	P	=	.001 0.10	(0.04,	0.17)	P	=	.001§§
ADL,	activities	of	daily	living;	AKPS,	Australian-Modified	Karnofsky	Performance	Status;	BI,	Barthel	Index;	FIM,	Functional	Independence	Measure;	IADL,	instrumental	activities	of	daily	living;	IRR,	Incident	Rate
Ratio;	NR,	not	reported;	NS,	not	significant;	OR,	odds	ratio;	SD,	standard	deviation;	SE,	standard	error.
∗ Adjusted	for	age,	sex,	education,	smoking,	mini-mental	state	examination	score,	ACBS	score	at	first	follow-up,	hypertension,	coronary	heart	disease,	renal	failure,	anemia,	and	infectious	diseases.
† Adjusted	for	sex,	ethnicity,	Charlson	comorbidity	index,	clinical	dementia	rating,	age,	Apolipoprotein	E	status,	education,	and	previous	weekly	function	performance.
‡ Adjusted	for	age,	sex,	body	mass	index,	smoking,	high	blood	pressure,	diabetes,	dyslipidemia,	heart	disease,	stroke,	and	dementia.
§ Adjusted	for	age,	sex,	time	from	surgery	to	rehabilitation,	admission	albumin	level,	education,	presence	of	caregiver,	residency,	mini-mental	state	examination	score,	admission	FIM,	ischemic	heart	disease,
congestive	heart	failure,	diabetes,	hypertension,	cardiovascular	disease,	depression,	Parkinson's,	and	chronic	obstructive	pulmonary	disease.
‖ Adjusted	for	age,	race,	years	of	education,	smoking,	physical	activity,	and	Charlson	comorbidity	index.
∗∗ Adjusted	for	schizophrenia,	depression,	cognitive	performance	scale	score,	age,	sex,	cumulative	index	rating	scale,	and	ADL	(baseline).
†† Adjusted	for	age,	sex,	Charlson	comorbidity	index,	abbreviated	mental	test,	total	of	other	medications,	and	Barthel	index	at	admission.
‡‡ Adjusted	for	time	before	death.
§§ Adjusted	for	age,	race,	education,	living	arrangement,	follow-up	year,	baseline	value	of	the	outcome,	ADL,	center-epidemiologic	studies	depression	scale,	smoking,	alcohol	use,	Charlson	comorbidity	index,	and
hypertension.
ARS	and	Physical	Function
Four	studies	with	sample	sizes	ranging	from	n	=	10530	to	n	=	149032	explored	relationships	between	ACB	and	physical	function	using	the	ARS	(Table	2).	Studies	varied	in	statistical	analysis	and	findings;	2	of	4	studies	reported
significant	association	between	baseline	ARS	and	future	functional	decline.30,32	Notably,	Brombo	et	al	2018,24	in	contrast	to	their	findings	using	the	ACBS,	failed	to	find	a	positive	association	between	function	and	ACB	using	the	ARS
measure	(odds	ratio	1.49,	95%	CI	0.60,	3.70).
Clinician	Rated	Anticholinergic	Score	and	Modified	Clinician	Rated	Anticholinergic	Score	and	Physical	Function
Two	studies	explored	relationships	between	ACB	and	physical	 function	using	the	Clinician	Rated	Anticholinergic	Score	(CRAS)	or	modified	CRAS	(mCRAS).23,26	Sample	sizes	ranged	from	n	=	46123	 to	n	=	544.26	 Agar	 et	al
(2009)23	reported	an	odds	ratio	0.85	(95%	CI	0.81,	0.90)	between	the	baseline	CRAS	of	older	palliative	care	patients	and	a	decrease	in	Australian-Modified	Karnofsky	Performance	Status	category;	those	with	higher	ACB	were	less	likely
to	be	classed	as	independent	at	follow-up.	Han	(2008)26	reported	an	effect	estimate	of	0.10	(95%	CI	0.04,	0.17)	suggesting	for	every	unit	increase	in	mCRAS	score	there	is	a	10%	reduction	in	IADL	(ie,	lower	independence).
Comparison	of	Prognostic	Ability	of	ACB	Measures	to	Predict	Future	Physical	Function
Only	2	studies	directly	compared	>1	ACB	measures	in	the	same	population;	Brombo	et	al	(2018)24	and	Pasina	et	al	(2013)34	both	compared	the	ACBS	and	ARS	abilities	to	predict	future	physical	function.	Brombo	et	al	(2018)24
reported	associations	with	the	ACBS	but	not	ARS,	while	Pasina	(2013)34	failed	to	find	a	significant	relationship	with	either	the	ACBS	or	ARS.
Quality	of	Life	Outcome	Studies
In	total	2635	older	people	participated	across	the	4	studies,	with	mean	(standard	deviation)	ages	ranging	from	71.0	(12.0)	years23	to	78.6	(6.7)	years.28	Two	studies	were	conducted	in	the	United	States.28,35	and	1e	each	from
Australia23	and	Canada.25	Further	details	of	each	study	are	presented	in	Table	1.
Risk	of	bias	 for	each	study	 (n	=	4)	 is	presented	 in	Figure	1.	Of	 the	4	 studies,	 2	 papers	were	 considered	high	 risk	 of	 bias	 in	≥1	QUIPS	categories.23,35	High	 bias	 risks	 arose	 from	 a	 lack	 of	 reporting	 of,	 or	 adjustment	 for,
confounders	and	unclear	analysis	plans.23,35	Moderate	risks	of	bias	were	common	throughout;	Participation	rates	were	rarely	reported,	the	number,	reasons	for	or	exploration	of	those	lost	to	follow-up	was	rarely	addressed,	along	with
non-reporting	of	missing	data.	A	funnel	plot	for	assessing	publication	bias	was	not	possible	due	to	variation	in	statistical	effect	sizes	presented	and	too	few	studies.
ACBS	and	Quality	of	Life
Two	studies,	with	sample	sizes	ranging	from	n	=	42628	to	n	=	179325	explored	the	relationship	between	baseline	ACB	and	quality	of	 life	using	the	ACBS.	Table	3	summarizes	results.	Cossette	 (2017)	 identified	a	significant
association	between	baseline	ACB	and	the	physical	domain	of	the	Short	Form	Health	Survey	36	(SF-36)	[β	−0.50	(95%	CI	−0.31,	−0.68)	P	<	.001)]	but	not	the	mental	domain	[β	0.19	(95%	CI	0.01,0.37)	P	=	ns].25	Conversely,	using	the
EuroQol	5D,	Ie	et	al	(2017)	did	not	identify	any	association	with	ACBS	score	over	12	months	[β	0.006	(95%	CI	−0.01	to	0.02)	P	=	ns)].28	Cossette	(2017)	do	not	present	results	combining	the	domains	of	the	SF-36	making	it	difficult	to
compare	the	2	sets	of	results.25
Table	3	Summary	of	Results	for	Studies	Exploring	Prognostic	Relationships	Between	ACB	and	QoL	(n	=	4)
Scale/Outcome Study ACB	(Baseline) QoL(Baseline)
Statistical
Approach Results	(Unadjusted) Results	(Adjusted)
ACBS	(Range	0–3)
 SF-36	PCS	(Range
0–100) Cossette	et	al	2017
25 ACBS	≥1:	33%
SF-36	PCS
(Mean,	SD):
49.0	(8.2)
Multiple	linear
regression
β	(95%	CI)
NR −0.50	(−0.31,	−0.68)	P	<	.001∗
 EQ-5D	(Range
0–1) Ie	et	al	2017
28 ACBS
Mean	(SD):	0.55	(0.87)
EQ-5D	(Mean,
SD):	0.82
(0.14)
Multiple	linear
regression
β,	SE	(95%	CI)
NR 0.006,	.009	(−0.01,	0.02)	P	=	NR†
ADS	(Range	0–3)
 SF-36	PCS	(Range
0–100) Cossette	et	al	2017
25 ACBS	≥1:	33%
SF-36	PCS
(Mean,	SD):
49.0	(8.2)
Multiple	linear
regression
β	(95%	CI)
NR −0.30	(−0.10,	−51)	P	<	.01∗
 SF-12	PCS	(Range
0–100) Sura	et	al	2016
35 Ach	user:	17	(15.2%) NR
Multiple	linear
regression
Parameter
estimate	(95%
CI)
NR −7.48	(−12.57,	−2.39)	P	<	.01‡
ARS	(Range	0–3)
 SF-36	PCS	(Range
0–100) Cossette	et	al	2017
25 ACBS	≥1:	33%
SF-36	PCS
(Mean,	SD):
49.0	(8.2)
Multiple	linear
regression
β	(95%	CI)
NR −0.43	(−0.69,	−0.17)	P	<	.01∗
mCRAS	(Range	0–3)
 MQoL	(Range
0–10) Agar	et	al	2009
23 NR
McGill	QOL
Mean	(SD):
6.0	(2.0)
Generalized
linear	models
OR	(95%	CI)
NR 0.90	(0.85,	0.95)	P	=	NR§
DBI-Ach	(Range	0–3)
 EQ-5D	(Range
DBI-Ach	(Mean,	SD):	0.05	(0.14)
EQ-5D	(Mean,
SD):	0.82
Multiple	linear
regression NR
0–1) Ie	et	al	201528 (0.14) β,	SE	(95%	CI) −0.09,	.05	(−19,	.002)	P	<	.05	†	b
EQ-5D,	EuroQol	5D;	MQoL,	MacGill	Quality	of	Life	Score;	NR,	not	reported;	OR,	odds	ratio;	QoL,	quality	of	life;	SF-12	PCS,	Short	Form	Health	Survey	12	Physical	health	Componentsite	Scores;	SE,	standard	error;	SF-
36	PCS,	Short	Form	Health	Survey	36	Physical	health	Composite	Scores.	Component.
∗ Adjusted	for	age,	sex,	education,	income,	living	alone,	frailty,	number	of	comorbidities,	modified	mini-mental	state	examination,	and	Geriatric	Depression	Scale.
† Adjusted	for	age,	sex,	living	with	someone,	income,	number.	of	comorbidities,	use	of	assistive	devices,	falls	<12	months,	baseline	DBI	ACH,	baseline	DBI-SEDSedatives,	baseline	ACBS,	number	of	regular
medications,	and	number	of	BEERBeers	list	medications.
‡ Adjusted	for	predisposing	factors	such	as	age,	race/ethnicity,	sex,	marital	status,	and	education.	Enabling	factors	included	family	income,	health	insurance	coverage,	region,	and	metropolitan	status	area.	Need
factors	comprised	of	perceived	general	and	mental	health	status,	ADL,	IADL,	and	cholinesterase	inhibitors.	The	baseline	PCShysical	health	Composite	Scores	and	MCSental	health	Composite	summary	scores	were
used	as	additional	need	factors.
§ Adjusted	for	time	before	death.
ADS	and	Quality	of	Life
Two	studies	with	sample	sizes	ranging	from	n	=	11235	to	n	=	179325	explored	relationships	between	ACB	and	physical	function	using	the	ADS	(Table	3).	Both	studies	demonstrated	moderate	significant	associations	between
increased	ACB	measured	by	the	ADS	and	the	physical	domain	of	the	SF-36	[β	−0.30	(95%	CI	−0.10,	−0.51)	P	<	.01]25	and	SF12	[est.	−7.48	(95%	CI	−12.57,	−2.39)	P	<	.01],35	respectively.	Neither	study	detected	association	between	the
ADS	and	the	mental	domains	of	the	SF-36	[β	−0.07	(95%	CI	−0.28,	0.13)	P	=	ns]	or	SF12	[Mean	between	group	difference	in	SF12	scores	−2.27	(95%	CI	−7.81,	3.27)	P	=	.43].25,35
ARS	and	Quality	of	Life
Only	1	study	explored	relationships	between	ACB	and	quality	of	life	using	the	ARS.25	Results	are	detailed	in	Table	3,	but	again	a	significant	association	with	the	physical,	but	not	the	mental,	domains	of	the	SF-36	were	identified.
DBI-Ach	Subscale	and	Quality	of	Life
Only	1	study	explored	the	relationship	between	DBI-Ach	and	quality	of	life,28	which	demonstrated	a	small	but	significant	relationship	with	reduced	quality	of	life	measured	by	the	EuroQol	5D	(Table	3).28
mCRAS	and	Quality	of	Life
Only	1	study	explored	the	relationship	between	mCRAS	and	quality	of	life,23	which	demonstrated	significant	association	with	the	McGill	Quality	of	Life	score	(Table	3).	Those	with	higher	ACB	scores	reported	poorer	quality	of
life	at	follow-up.23
Comparison	of	Prognostic	Ability	of	ACB	Measures	to	Predict	Future	Quality	of	Life
Only	2	studies	directly	compared	different	ACB	measures	in	the	same	population	sample;	Cossette	et	al	(2017)25	compared	3	measures	(ACBS,	ADS	ARS),	whereas	Ie	et	al	(2016)28	compared	the	ACBS	and	DBI-Ach,	to	predict
quality	of	life.	The	ACBS	demonstrated	the	strongest	associations	in	comparison	to	the	ADS	and	ARS.25	Ie	et	al	(2016)	demonstrated	a	stronger	relationship	using	the	DBI-Ach	than	the	ACBS,	however	associations	were	very	small
(β	−0.095,	P	<	.05).28
GRADE	Assessment
All	GRADE	assessments	conducted	for	each	ACB	scale	and	outcome	combination	resulted	in	an	assessment	of	“very	low,”	meaning	that	we	have	little	confidence	in	the	results	and	further	studies	will	likely	change	the	results.
Quality	was	commonly	downgraded	due	to	serious	concerns	regarding	study	biases,	inconsistency	in	results,	indirectness,	potential	for	publication	bias	and	small	effect	sizes	(Supplementary	File	1	for	detailed	GRADE	assessments).
Discussion
This	systematic	review	included	13	studies	reporting	the	prognostic	value	of	1	or	more	ACB	measures	in	relation	to	physical	function	or	quality	of	life	in	older	people.	Seven	out	of	10	studies	reported	a	significant	association
between	increased	ACB	and	future	impaired	physical	function,	with	the	remaining	studies	showing	a	nonsignificant	trend	toward	this.	However,	statistical	and	clinical	heterogeneity	prevents	meta-analysis	and	our	ability	to	recommend
one	measure	above	another.	In	relation	to	quality	of	life,	4	studies	reported	the	longitudinal	relationships	between	ACB	and	quality	of	life	among	older	people.	Each	study	reported	at	least	1	significant	association	between	ACB	and
quality	of	life,	but	again	limited	evidence	prevents	recommending	one	measure	above	another.	At	present,	the	evidence	behind	the	ability	of	individual	ACB	measures	to	predict	future	physical	function	and	quality	of	life	is	poor	and
does	not	permit	 informed	decisions	regarding	which	measure	 is	best	 to	assess	ACB.	We	conclude	that,	 in	relation	to	older	people,	ACB	shows	a	general	 trend	toward	 impaired	physical	 function	and	reduced	quality	of	 life	but	the
question	as	to	which	ACB	measure	performs	best	remains	unanswered.
In	the	review	by	Fox	et	al	(2014),5	studies	which	failed	to	associate	ACB	and	physical	function	often	focused	upon	single	domain	aspects	of	function	(eg,	walking	ability).	Our	study	excluded	such	outcomes	to	focus	upon	global
measures	that	are	more	comparable	between	populations.	However,	it	has	been	suggested	that	specific	domains	of	physical	function	such	as	gait	may	play	important	mediating	roles	between	ACB	and	other	adverse	outcomes	such	as
falls.36	Research	focusing	upon	the	temporal	relationship	between	ACB	and	global	physical	function,	specific	physical	abilities	and	how	these	relate	to	other	outcomes	are	required	to	advance	our	understanding	of	the	complexities	of
this	relationship.
Our	findings	support	a	general	trend	for	increased	ACB	being	associated	with	a	reduction	in	quality	of	life;	however,	the	evidence	is	limited	by	few	studies	and	low	study	quality.	The	divergence	in	results	between	domains	of
quality	of	life,	demonstrating	greatest	associations	with	the	physical	domain	of	quality	of	life	than	the	mental	domain,	is	not	unique	to	ACB.	Similar	results	were	recently	published	in	relation	to	associations	between	multi-morbidity
and	quality	of	life	where	strong	associations	with	physical,	but	not	mental	domains	were	also	found.37	Exploration	of	older	peoples	perspectives	toward	ACB	and	its	impact	upon	quality	of	life	is	necessary	to	further	understand	what
aspects,	if	any,	ACB	is	perceived	to	impact	upon,	which	may	help	explain	this	finding.
The	number	of,	and	variations	between	ACB	measures,	has	been	documented	previously.13,38	Many	were	developed	 to	 target	specific	adverse	outcomes,	most	commonly	cognitive	 impairment	and	dementia.13,38	These	may
nevertheless	be	associated	with	the	outcomes	assessed	in	this	review	because	cognitive	impairment	is	associated	with	poorer	physical	function39	and	quality	of	life,40	and	because	anticholinergics	are	well	known	to	have	many	other
adverse	effects	beyond	cognitive	impairment.	Reliance	upon	expert	rated	anticholinergic	potency	is	troublesome	due	to	divergent	views	amongst	clinicians.13,38	Conversely	attempts	to	rate	anticholinergic	potency	objectively	is	not
without	its	limitations,	not	least	discordance	between	measurable	biological	markers	and	symptoms	of	anticholinergic	properties.13,38	Despite	our	intentions	this	present	review	cannot	answer	the	question	as	to	which	ACB	measure
may	be	most	suitable	for	predicting	specific	outcomes.	The	small	number	of	studies,	diverse	range	of	outcome	measures,	and	substantial	differences	in	study	characteristics	means	determining	one	ACB	measure	as	being	a	better
predictor	of	future	physical	function	or	quality	of	life	is	not	possible.	To	improve	prognostic	research	future	research	should	be	prospective	longitudinal	or	case-control	in	design	and	sufficiently	large,	with	sample	size	calculations
appropriate	for	the	outcome	of	interest	and	adjust	for	important	confounding	variables.
The	strengths	of	this	systematic	review	include	its	novelty	in	both	focusing	upon	comparing	ACB	measures	and	being	restricted	to	older	people.	Other	strengths	include	its	comprehensive	search	strategy	using	a	validated
search	filter	to	identify	relevant	studies,	reference	list	checks	of	all	included	studies	and	any	seminal	studies	not	included	to	ensure	no	eligible	studies	were	omitted,	and	our	decision	to	focus	on	longitudinal	and	case-control	studies
more	suited	to	understanding	adverse	outcomes.	However,	this	review	also	has	some	limitations.	We	did	not	include	gray	literature;	while	this	can	help	avoid	contaminating	results	with	low	quality	non-peer	reviewed	evidence,	we
cannot	say	with	certainty	that	its	exclusion	did	not	result	in	the	omission	of	insightful	and	relevant	papers.	Finally,	the	small	number	of	studies	identified	meant	it	was	not	possible	to	adequately	assess	for	publication	bias	so	we	have	to
assume	there	is	a	possibility	of	this.
Conclusions	and	Implications
This	systematic	review	identified	13	studies	reporting	the	prognostic	value	of	one	or	more	ACB	measures	in	relation	to	physical	function	or	quality	of	life.	The	majority	of	studies	show	at	least	a	general	trend	toward	impaired
function	and	reduced	quality	of	 life	associated	with	 increased	ACB.	At	present	 the	evidence	behind	 individual	ACB	measures'	ability	 to	predict	physical	 function	and	quality	of	 life	among	older	adults	 is	poor	and	does	not	permit
informed	decisions	 regarding	which	 is	 the	 best	measure	 to	 use.	Well-designed	 longitudinal	 studies	 are	 required	 to	 address	 this.	However,	 the	 general	 consistency	 in	 our	 findings,	 alongside	 the	wider	 body	 of	 evidence,	 suggests
clinicians	should	continue	to	be	aware	of	individual	patients'	ACB	and	consider	alternatives	to	anticholinergic	medications	where	appropriate.
Supplementary	Data
Supplementary	data	related	to	this	article	can	be	found	online	at	https://doi.org/10.1016/j.jamda.2020.05.065.
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